文献速递消化系统肿瘤

转移性结直肠癌不同治疗方案中卡培他滨相关心脏毒性的发生率:荷兰结直肠癌协作组CAIRO系列研究的回顾性分析

Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
PubMed 文献 · Eur J Cancer · 2017-03-10

该回顾性分析纳入三项随机3期研究(CAIRO、CAIRO2、CAIRO3)中使用卡培他滨方案治疗的1973例转移性结直肠癌患者,共2461线治疗。总体5.9%(117例)发生至少一次心脏事件,2.3%(46例)发生至少一次≥3级事件;卡培他滨联合奥沙利铂和贝伐珠单抗组心脏事件发生率最高(12%,43例)。

要点

  • 总体卡培他滨相关心脏事件发生率为5.9%(117/1973),≥3级事件为2.3%(46/1973)。
  • 最常见事件为缺血/梗死(2.9%,57例),其次为心律失常(2.0%,40例,其中心房颤动10例)。
  • 卡培他滨联合奥沙利铂和贝伐珠单抗组心脏事件发生率最高(12%,43例)。

核心结论

  • 卡培他滨相关心脏毒性见于5.9%的患者,严重心脏毒性见于2.3%的患者。
  • 卡培他滨联合奥沙利铂和贝伐珠单抗治疗与最高的心脏毒性风险相关。

研究设计与样本

  • 回顾性分析荷兰结直肠癌协作组(DCCG)CAIRO、CAIRO2和CAIRO3三项随机3期研究中报告的心脏事件。
  • 共纳入1973例接受卡培他滨为基础方案治疗的转移性结直肠癌患者,共2461线治疗。
  • 心脏事件按美国国立癌症研究所常见毒性标准(NCI-CTC)分级。

主要发现

  • 总体5.9%(n=117)的患者发生至少一次心脏事件,2.3%(n=46)发生至少一次≥3级事件;3例患者发生两次心脏事件。
  • 最常见心脏事件为缺血/梗死(2.9%,n=57),其次为心律失常(2.0%,n=40,其中心房颤动10例)、胸痛(0.8%,n=16)和心力衰竭(0.4%,n=7)。
  • 卡培他滨联合奥沙利铂和贝伐珠单抗组心脏事件发生率最高(12%,n=43)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The frequency of capecitabine-related cardiotoxicity has been reported to be low but includes serious adverse events. We conducted a retrospective analysis of the incidence and severity of capecitabine-related cardiotoxicity in different regimens in the treatment of metastatic colorectal cancer in three randomised phase 3 studies. METHODS: We used data of cardiac events reported in the CAIRO, CAIRO2 and CAIRO3 studies of the Dutch Colorectal Cancer Group (DCCG) and analysed the incidence and severity of cardiac events in the different treatment regimens of the trials which all included the use of capecitabine. The following events were included: chest pain, newly diagnosed cardiac ischaemia/infarction, atrial fibrillation, other arrhythmias and heart failure, all graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC). RESULTS: A total of 1973 patients were included, who received a total of 2461 capecitabine-based lines of treatment. Overall, 5.9% of patients (n = 117) experienced at least one cardiac event, and 2.3% (n = 46) experienced at least one grade ≥3 event. Three patients had two cardiac events. The most frequently observed cardiac event was ischaemia/infarction (2.9%, n = 57), followed by arrhythmias (2.0%, n = 40, including atrial fibrillation in 10 patients), chest pain (0.8%, n = 16) and heart failure (0.4%, n = 7). The highest incidence of cardiac events was observed in patients treated with capecitabine in combination with oxaliplatin and bevacizumab (12%, n = 43). CONCLUSION: We observed capecitabine-related cardiotoxicity in 5.9% of patients, and severe cardiotoxicity in 2.3% of patients. Combination treatment with capecitabine, oxaliplatin and bevacizumab was associated with the highest risk of cardiotoxicity.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kwakman JJ, Simkens LH, Mol L, et al. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. Eur J Cancer. 2017. PMID: 28286287. doi:10.1016/j.ejca.2017.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。